Dr. Robert P. Schwartz

Robert P. Schwartz, M.D.

Robert P. Schwartz, M.D.
Robert P. Schwartz, M.D.
Medical Director/Senior Research Scientist

M.D., University of Padua, Italy
rschwartz@friendsresearch.org
Phone: 410-837-3977 ext. 276
Fax: 410-752-4218
Research Interests

Dr. Schwartz, FRI’s Medical Director, is a psychiatrist and former Director of the Division of Alcohol and Drug Abuse in the Department of Psychiatry at the University of Maryland School of Medicine. His research interests include entry and engagement in drug abuse treatment, pharmacotherapy of opioid dependence in community and in criminal justice settings, and screening and brief intervention for drug misuse in primary care settings. He has served as Principal Investigator (PI) of numerous National Institute on Drug Abuse (NIDA) funded clinical trials. Currently, Dr. Schwartz is PI of a NIDA and Arnold Foundation-funded study of methadone treatment and patient navigation in jail.  Dr. Schwartz is the Multi-PI along with Dr. Maxine Stitzer from Johns Hopkins University for the Mid-Atlantic Node of the NIDA Clinical Trials Network. He has over 150 scientific publications, is the winner of the Dole-Nyswander Award from the American Association for the Treatment of Opioid Dependence, and is the Chair of the Substance Abuse and Mental Health Services Administration’s Toolkit for Improving Practice (TIP) on Medications for the Treatment of Opioid Use Disorder.

Selected Publications
Gordon MS, Blue TR, Couvillion K, Schwartz RP, O’Grady KE, Fitzgerald TT & Vocci FJ (in press). Impact of Starting Buprenorphine Treatment Prior to vs. After Release from Prison: Arrest Outcomes. Drug and Alcohol Dependence.
Monico LB, Gryczynski J, Schwartz RP, Jaffe JH, O’Grady KE, & Mitchell SG (in press). Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12-months. American Journal of Drug and Alcohol Abuse.
Gryczynski J, Carswell SB, O’Grady KE, Mitchell SG, Schwartz RP (2018). Gender and ethnic differences in primary care patients' response to computerized vs. in-person brief intervention for illicit drug misuse. Journal of Substance Abuse Treatment. 84:50-56. doi: 10.1016/j.jsat.2017.10.009.
Mitchell SG, Monico LB, Lertch E, Kelly SM, Gryczynski J, Jaffe J, O’Grady KE, & Schwartz RP (2018). Counseling staff's views of patient-centered methadone treatment: Changing program rules and staff roles. Journal of Behavioral Health Services and Research.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug and Alcohol Dependence. 172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11. PMID: 28107680.
Gryczynski J, McNeely J, Wu LT, Subramaniam GA, Svikis DS, Cathers LA, Sharma G, King J, Jelstrom E, Nordeck CD, Sharma A, Mitchell SG, O’Grady KE, Schwartz RP (2017). Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care. Journal of General Internal Medicine. 32(9):990-996. doi: 10.1007/s11606-017-4079-x. Epub 2017 May 26. PMID: 28550609.
Gryczynski J, Nordeck CD, Mitchell SG, Page KR, Johnsen LL, O’Grady KE, Schwartz RP (2017). Pilot Studies Examining Feasibility of Substance Use Disorder Screening and Treatment Linkage at Urban Sexually Transmitted Disease Clinics. Journal of Addiction Medicine. 11(5):350-356. doi: 10.1097/ADM.0000000000000327. PMID: 28590392.
Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M (2017). Pregnant Women's Current and Intended Cannabis Use in Relation to Their Views Toward Legalization and Knowledge of Potential Harm. Journal of Addiction Medicine. 11(3):211-216. doi: 10.1097/ADM.0000000000000299. PMID:28252456.
Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Gandhi D, Olsen Y, Jaffe JH (2017). Patient‐centered methadone treatment: a randomized clinical trial. Addiction. 112(3):454-64.
Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Jaffe JH (2017). When does methadone treatment reduce arrest and severity of arrest charges? An analysis of arrest records. Drug and Alcohol Dependence. 180:385-390. doi: 10.1016/j.drugalcdep.2017.08.025. Epub 2017 Sep 14. PMID: 28961545.
Schwartz RP, McNeely J, Wu LT, Sharma G, Wahle A, Cushing C, Nordeck CD, Sharma A, O’Grady KE, Gryczynski J, Mitchell SG, Ali RL, Marsden J, Subramaniam G (2017). Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. Journal of Substance Abuse Treatment. 76, 69-76.
Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP (2017). Update on Barriers to Pharmacotherapy for Opioid Use Disorders. Current Psychiatry Reports. 19(6):35. doi: 10.1007/s11920-017-0783-9. Review. PMID: 28526967.
Sigmon SC, Schwartz RP, Higgins ST (2017). Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence. New England Journal of Medicine. 376(10):1000-1001. doi: 10.1056/NEJMc1700539. No abstract available. PMID: 28273017.
Stitzer ML, Schwartz RP, Bigelow GE (2017). Prescription opioids: New perspectives and research on their role in chronic pain management and addiction. Drug and Alcohol Dependence. 173 Suppl 1:S1-S3. doi: 10.1016/j.drugalcdep.2016.11.018. No abstract available. PMID: 28363314.
Wu LT, McNeely J, Subramaniam GA, Brady KT, Sharma G, VanVeldhuisen P, Zhu H, Schwartz RP (2017). DSM-5 substance use disorders among adult primary care patients: Results from a multisite study. Drug and Alcohol Dependence. 179:42-46. doi: 10.1016/j.drugalcdep.2017.05.048. Epub 2017 Jul 13. PMID: 28753480.
Chandler RK, Finger MS, Farabee D, Schwartz RP, Condon T, Dunlap LJ, Zarkin GA, McCollister K, McDonald RD, Laska E, Bennett D, Kelly SM, Hillhouse M, Mitchell SG, O’Grady KE, Lee J (2016). The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings. Contemporary Clinical Trials. 48:166-72. doi: 10.1016/j.cct.2016.05.003. PMID: 27180088.
Gryczynski J, O’Grady KE, Mitchell SG, Ondersma SJ, Schwartz RP (2016). Immediate Versus Delayed Computerized Brief Intervention for Illicit Drug Misuse. Journal of Addiction Medicine. 10(5):344-51. doi: 10.1097/ADM.0000000000000248. PMID: 27504925.
Gryczynski J, Schwartz RP, O’Grady KE, Restivo LL, Mitchell SG, Jaffe JH (2016). Understanding patterns of high-cost health care use across different substance user groups. Health Affairs. (Millwood). 35(1):12-9. doi: 10.1377/hlthaff.2015.0618. PMID: 26733696 PMCID: PMC4936480 DOI: 10.1377/hlthaff.2015.0618.
McNeely J, Wu LT, Subramaniam G, Sharma G, Cathers LA, Svikis D, Sleiter L, Russell L, Nordeck C, Sharma A, O’Grady KE, Bouk LB, Cushing C, King J, Wahle A, Schwartz RP (2016). Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Annals of Internal Medicine. 165(10):690-699. doi: 10.7326/M16-0317. PMID: 27595276.
Mitchell SG, Willett J, Monico LB, James A, Rudes DS, Viglioni J, Schwartz RP, Gordon MS, Friedmann PD (2016). Community Correctional Agents' Views of Medication-Assisted Treatment: Examining their Influence on Treatment Referrals and Community Supervision Practices. Substance Abuse. 37(1):127-33. doi: 10.1080/08897077.2015.1129389. PMID: 26860334. PMCID: PMC4823810.
Monico LB, Mitchell SG, Welsh W, Link N, Hamilton L, Malvini Redden S, Schwartz R, & Friedmann P (2016). Developing effective interorganizational relationships between community corrections and community treatment providers. Journal of Offender Rehabilitation.
Monico LB, Schwartz RP, Gryczynski J, O’Grady KE, & Mitchell SG (2016). Two models of integrating buprenorphine treatment and medical staff within formerly “drug-free” outpatient programs. Journal of Psychoactive Drugs.
Ondersma SJ, Gryczynski J, Mitchell SG, O’Grady KE, Schwartz RP (2016). Process evaluation of a technology-delivered screening and brief intervention for substance use in primary care. Internet Interventions. 4(Pt 1):11-16. PMID: 27110494PMCID: PMC4836054. DOI: 10.1016/j.invent.2016.01.004.
Schwartz RP (2016). When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al. Journal of Addiction Medicine. 10(4):283-5. doi: 10.1097/ADM.0000000000000236. PMID: 27471920.
Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O’Grady KE, Jaffe JH (2016). Corrigendum to “Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial”. Contemporary Clinical Trials. 51:97. doi: 10.1016/j.cct.2016.09.008. PMID: 27729206.
Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O’Grady KE, Jaffe JH (2016). Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial. Contemporary Clinical Trials. 49:21-8. doi: 10.1016/j.cct.2016.06.002. PMID: 27282117.
Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Gandhi D, Olsen Y, Jaffe JH (2016). Patient-centered methadone treatment: a randomized clinical trial. Addiction. doi: 10.1111/add.13622. [Epub ahead of print]. PMID: 27661788.
Serpelloni G, Genetti B, Andreotti A, Sperotto M, Zermiani M, Sharma A, O’Grady KE, Schwartz RP (2016). Prevalence and correlates for alcohol, cigarette, and cannabis use among Italian high school students: a national survey. Substance Abuse and Rehabilitation.
Sharma A, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP (2016). Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Substance Abuse and Rehabilitation. 7:27-40. doi: 10.2147/SAR.S81602. Review. PMID: 27217808. PMCID: PMC4853155 DOI: 10.2147/SAR.S81602.
Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, Rose G, Brooklyn JR, Schwartz RP, Moore BA, Higgins ST (2016). Interim Buprenorphine vs. Waiting List for Opioid Dependence. New England Journal of Medicine. 375(25):2504-2505. doi: 10.1056/NEJMc1610047. PMID: 28002704. DOI: 10.1056/NEJMc1610047.
Wu LT, McNeely J, Subramaniam G, Sharma G, VanVelduisen P, Schwartz RP (2016). Design of the NIDA Clinical Trials Network Validation Study of Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse (TAPS) Tool. Contemporary Clinical Trials. 50:90-7. doi: 10.1016/j.cct.2016.07.013. PMID: 27444426.
Wu LT, McNeely J, Subramaniam GA, Sharma G, VanVeldhuisen P, Schwartz RP (2016). Corrigendum to "Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool" [Contemporary Clinical Trials. 19; 50: 90-97]. Contemporary Clinical Trials. 51:98. doi: 10.1016/j.cct.2016.09.001. PMID: 27665683.
Barbosa C, Dunlap LJ, Wedehase B, Mitchell SG, Schwartz RP, Dušek K, Kirk AS, Oros M, Hosler C, Gryczynski J, Brown BS (2015). Start-up costs of implementing Screening and Brief Intervention (SBI) for Adolescents (part of Economics of SBI symposium). Addiction Science and Clinical Practice. 10 (Suppl 2), O5.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O’Grady KE, Vocci FJ, Shabazz H (2015). Buprenorphine Treatment for Probationers and Parolees. Substance Abuse. 36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4. PMID: 24701967.
Gryczynski J, Kelly SM, Mitchell SG, Kirk A, O’Grady KE, Schwartz RP (2015). Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients. Addiction. 110(2):240-7. doi: 10.1111/add.12767. Epub 2014 Nov 20. PMID: 25311148.
Gryczynski J, Mitchell SG, Gonzales A, Moseley A, Peterson TR, Ondersma SJ, O’Grady KE, Schwartz RP (2015). A randomized trial of computerized vs. in-person brief intervention for illicit drug use in primary care: outcomes through 12 months. Journal of Substance Abuse Treatment. 50, 3-10. doi: 10.1016/j.jsat.2014.09.002. Epub 2014 Sep 16. PMID: 25282578.
Gryczynski J, Mitchell SG, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP (2015). Leaving buprenorphine treatment: patients' reasons for cessation of care. Journal of Substance Abuse Treatment. 46(3):356-61. PubMed PMID: 24238714; PubMed Central PMCID: PMC3947058.
Gryczynski J, Mitchell SG, Ondersma SJ, O’Grady KE, Schwartz RP (2015). Potential radiating effects of misusing substances among medical patients receiving brief intervention. Journal of Substance Abuse Treatment. 55:39-44.
Gryczynski J, Nordeck C, Mitchell SG, O’Grady KE, McNeely J, Wu L-T, Schwartz RP (2015). Reference periods in retrospective behavioral self-report: A qualitative investigation. American Journal on Addictions. 24(8): 744-747.
Gryczynski J, Schwartz RP, Mitchell SG, Dzirasa L, Dušek K, O’Grady K, and Cowell A (2015). Preliminary research in preparation for a randomized trial of brief intervention strategies for adolescents in school-based health centers. Addiction Science and Clinical Practice. 10 (Suppl 2), O20. http://doi.org/10.1186/1940-0640-10-S2-O20.
Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O’Grady KE, Olsen YK, Jaffe JH (2015). Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. Journal of Psychoactive Drugs. 47(2):149-57.
Mitchell SG, Monico LB, Gryczynski J, O’Grady KE, Schwartz RP (2015). Staff Views of Acceptability and Appropriateness of a Computer-Delivered Brief Intervention for Moderate Drug and Alcohol Use. Journal of Psychoactive Drugs. 47(4):301-7. doi: 10.1080/02791072.2015.1075631. Epub 2015 Sep 16. PMID: 26375411.
Mitchell SG, Schwartz RP, Alvanzo AA, Weisman MS, Kyle TL, Turrigiano EM, Gibson ML, Perez L, McClure EA, Clingerman S, Froias A, Shandera DR, Walker R, Babcock DL, Bailey GL, Miele GM, Kunkel LE, Norton M, Stitzer ML (2015). The Use of Technology in Participant Tracking and Study Retention: Lessons Learned from a Clinical Trials Network Study. Substance Abuse. 36(4):420-6. doi: 10.1080/08897077.2014.992565. Epub 2015 Feb 11. PMID: 25671593. PMCID: PMC4532645.
Mitchell SG, Willett J, Swan H, Monico LB, Yang Y, Patterson Y, Belenko S, Vega-Debien Graciela Pankow J, Schwartz RP and Visher C (2015). Defining success: Insights from a random assignment, multi-site study of implementing HIV prevention, testing and linkage to care in US jails and prisons. AIDS Education and Prevention. 27(5):432-45. doi: 10.1521/aeap.2015.27.5.432. PMID: 26485233.
Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O’Grady KE, Jaffe JH (2015). Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. Journal of Substance Abuse Treatment.   57:89-95. doi: 10.1016/j.jsat.2015.05.005. Epub 2015 May 12. PMID: 25986647.
Monico LB, Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH (2015). Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention. Journal of Substance Abuse Treatment. 57:57-62. doi: 10.1016/j.jsat.2015.04.010. Epub 2015 May 7. PMID: 25980599.
Peters EN, Nordeck C, Zanetti G, O’Grady KE, Serpelloni G, Rimondo C, Blanco C, Welsh C, Schwartz RP (2015). Relationship of gambling with tobacco, alcohol, and illicit drug use among adolescents in the USA: Review of the literature 2000-2014. American Journal on Addictions. 24(3):206-16.
Schwartz RP, Kelly SM, Gryczynski J, Mitchell SG, O’Grady KE, Jaffe JH (2015). Heroin use, HIV-risk, and criminal behavior in Baltimore: Findings from Clinical Research. Journal of Addictive Diseases. 34(2-3):151-61. doi: 10.1080/10550887.2015.1059222. PMID: 26079104.
Sigmon SC, Meyer AC, Hruska B, Ochalek T, Rose G, Badger GJ, Brooklyn JR, Heil SH, Higgins ST, Moore BA, Schwartz RP (2015). Bridging waitlist delays with Interim Buprenorphine Treatment: Initial feasibility. Addictive Behaviors. 51:136-142.
Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O’Grady KE, Jaffe JH (2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug and Alcohol Dependence. 156:133-8. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7. PMID: 26409751.
Bellamoli E, Manganotti P, Schwartz RP, Rimondo C, Gomma M, Serpelloni G (2014). rTMS in the treatment of drug addiction: an update about human studies. Behavioural Neurology. 2014:815215. PubMed PMID: 24803733; PubMed Central PMCID: PMC4006612.
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ (2014). A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug and Alcohol Dependence. 142, 33-40. doi: 10.1016/j.drugalcdep.2014.05.011. Epub 2014 Jun 2. PMID: 24962326.
Gryczynski J, Schwartz RP, Mitchell SG, O’Grady KE, Ondersma SJ (2014). Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use. Drug and Alcohol Dependence. 141:44-50. doi: 10.1016/j.drugalcdep.2014.05.001. Epub 2014 May 17. PMID: 24932945. PMCID: PMC4080811.
Holtyn AF, Koffarnus MN, DeFulio A, Sigurdsson SO, Strain EC, Schwartz RP, Leoutsakos JM, Silverman K (2014). The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Preventative Medicine. 68:62-70. Epub 2014 Mar 4.PMID: 24607365.
Holtyn AF, Koffarnus MN, DeFulio A, Sigurdsson SO, Strain EC, Schwartz RP, Silverman K (2014). Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. Journal of Applied Behavior Analysis. 47(4):681-93. doi: 10.1002/jaba.158. Epub 2014 Oct 8. PMID: 25292399.
Kelly SM, Gryczynski J, Mitchell SG, Kirk A, O’Grady KE, Schwartz RP (2014). Concordance between DSM-5 and DSM-IV nicotine, alcohol, and cannabis use disorder diagnoses among pediatric patients. Drug and Alcohol Dependence. 140:213-6. PubMed PMID: 24793367; PubMed Central PMCID: PMC4070874.
Kelly SM, Gryczynski J, Mitchell SG, Kirk A, O’Grady KE, Schwartz RP (2014). Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use. Pediatrics. 133(5):819-26. PubMed PMID: 24753528; PubMed Central PMCID: PMC4006430.
Mitchell SG, Gryczynski J, Kelly SM, O’Grady KE, Jaffe JH, Olsen YK, Schwartz RP (2014). Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status. Journal of Drug Issues. 44(1):69-82. PMID:25364037.
Mitchell SG, Kelly SM, Gryczynski J, Myers CP, O’Grady KE, Kirk AS, Schwartz RP (2014). The CRAFFT Cut-Points and DSM-5 Criteria for Alcohol and Other Drugs: A Reevaluation and Reexamination. Substance Abuse. 35(4):376-80. PubMed PMID: 25036144; PubMed Central PMCID: PMC4268117.
Peters EN, Schwartz RP, Wang S, O’Grady KE, Blanco C (2014). Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence. Drug and Alcohol Dependence. 134:228-34. PubMed PMID: 24183498; PubMed Central PMCID: PMC3865597.
Schwartz RP, Alexandre PK, Kelly SM, O’Grady KE, Gryczynski J, Jaffe JH (2014). Interim versus standard methadone treatment: a benefit-cost analysis. Journal of Substance Abuse Treatment. 46(3):306-14. doi: 10.1016/j.jsat.2013.10.003. Epub 2013 Oct 14.PMID:24239030.
Schwartz RP, Gryczynski J, Mitchell SG, Gonzales A, Moseley A, Peterson TR, Ondersma SJ, O’Grady KE (2014). Computerized versus in-person brief intervention for drug misuse: a randomized clinical trial. Addiction. 109(7):1091-8. doi: 10.1111/add.12502. Epub 2014 Mar 10. PMID: 24520906. PMCID: PMC4086904.
Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser Y-I, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W (2014). Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the Starting Treatment with Agonist Replacement Therapies (START) study. Journal of Psychoactive Drugs. 46(5):412-26. doi: 10.1080/02791072.2014.921743. PMID: 25364994.
Blanco C, Iza M, Schwartz RP, Rafful C, Wang S, Olfson M (2013). Probability and predictors of treatment-seeking for prescription opioid use disorders: a national study. Drug and Alcohol Dependence. 131 (1-2), 143-148.
Blanco C, Rafful C, Wall MW, Jin CJ, Kerridge B, Schwartz RP (2013). The latent structure and predictors of non-medical prescription drug use and prescription drug use disorders: a national study. Drug and Alcohol Dependence. 133(2), 473-479.
Defulio A, Stitzer M, Roll J, Petry N, Nuzzo P, Schwartz RP, et al (2013). Criminal justice referral and incentives in outpatient substance abuse treatment. Journal of Substance Abuse Treatment. 45. (1), 70-75.
Gordon MS, Kinlock TW, Couvillion KA, Schwartz RP, Wilson ME, O’Grady KE (2013). Gender differences among prisoners with pre-incarceration heroin dependence participating in a randomized clinical trial of buprenorphine treatment. Journal of Offender Rehabilitation. 52(5), 376-391.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, O’Grady KE (2013). The Severity, Frequency, and Variety of Crime in Heroin-Dependent Prisoners Enrolled in a Buprenorphine Clinical Trial. Prison Journal. 93(4):390-410.
Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, O’Grady KE, Olsen YK, Mitchell SG (2013). Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. American Journal on Addictions. 22(3):285-91.
Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O’Grady KE, Olsen YK, Schwartz RP (2013). Retention in methadone and buprenorphine treatment among African Americans. Journal of Substance Abuse Treatment. 45(3):287-92.
Kelly SM, O’Grady KE, Jaffe JH, Gandhi D, Schwartz RP (2013). Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment . Journal of Addiction Medicine. 7 (2), 133-138.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2013). Individual Patient and Program Factors Related to Prison and Community Treatment Completion in Prison-Initiated Methadone Maintenance Treatment. Journal of Offender Rehabilitation. 52(8):509-528.
Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP (2013). SBIRT for adolescent drug and alcohol use: current status and future directions. Journal of Substance Abuse Treatment. 44 (5), 463-472.
Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH (2013). A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug and Alcohol Dependence. 128 (3), 222-229.
Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. American Journal of Public Health.  103(5):917-22.
Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen YK, Mitchell SG, Jaffe JH (2013). Schwartz et al. respond. American Journal of Public Health. 2013 103(8):e2-3..Epub 2013 Jun 13.
Schwartz RP, Stitzer ML, Feaster DJ, Korthuis PT, Alvanzo AA, Winhusen TM, et al (2013). HIV rapid testing in drug treatment: comparison across treatment modalities. Journal of Substance Abuse Treatment. 44. (4), 369-374.
Serpelloni G, Gomma M, Genetti B, Zermiani M, Rimondo C, Mollica R, Gryczynski J, O’Grady KE, Schwartz RP (2013). Italy’s electronic health record system for opioid agonist treatment. Journal of Substance Abuse Treatment. 45(2):190-5.
Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PDNunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O’Brien CP (2012). A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse. 33 (1), 48-59. [PMCID: PMC3365863].
Friedmann PD, Hoskinson R, Gordon MS, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O’Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Substance Abuse. 33 (1), 9-18. [PMCID: PMC3295578].
Friedmann PD, Schwartz RP (2012). Just call it "treatment". Addiction Science and Clinical Practice 7. (1), 10.
Gonzales A, Westerberg VS, Peterson TR, Moseley A, Gryczynski J, Mitchell SG, Buff G, Schwartz RP (2012). Implementing a statewide Screening, Brief Intervention, and Referral to Treatment (SBIRT) service in rural health settings: New Mexico SBIRT. Substance Abuse. 33 (2), 114-123. [PMCID: PMC3325793].
Gordon MS, Kinlock TW, Couvillion K, Schwartz RP, O’Grady KE (2012). A randomized clinical trial of methadone maintenance for prisoners: Prediction of treatment entry and completion in prison. Journal of Offender Rehabilitation. 51 (4), 222-238.
Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP (2012). Opioid agonist maintenance for probationers: Patient-level predictors of treatment retention, drug use, and crime. Substance Abuse. 33 (1), 30-39.
Kelly SM, Brown BS, Katz EC, O’Grady KE, Mitchell SG, King S, Schwartz RP (2012). A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients. The American Journal of Drug and Alcohol Abuse. 38 (3), 233-238.
Kelly SM, Schwartz RP, O’Grady KE, Gandhi D, Jaffe JH (2012). Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. Journal of Addiction Medicine. 6 (2), 145-152. [PMCID: PMC3322294].
Mitchell SG, Gryczynski J, Peterson T, Gonzales A, Moseley A, Schwartz RP (2012). Screening, Brief Intervention, and Referral to Treatment (SBIRT) for substance use in a school-based program: Services and outcomes. American Journal on Addictions. 21 S5-S13.
Mitchell SG, Kelly SM, Brown BS, O’Grady KE, Schwartz RP (2012). HIV sex-risk behaviors among in- versus out-of-treatment heroin-addicted adults. American Journal of Drug and Alcohol Abuse. 38 (4), 328-333.
Mitchell SG, Kelly SM, Gryczynski J, Myers CP, Jaffe JH, O’Grady KE, Olson YK, Schwartz RP (2012). African-American patients seeking treatment in the public sector: Characteristics of buprenorphine v. methadone patients. Drug and Alcohol Dependence. 122, 55-60. [PMCID: PMC3251709].
Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH (2012). Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction. 107 (5), 943-952. [PMCID: PMC3319854].
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. The American Journal on Addictions. 21 (5), 476-487.
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison HIV-risk behaviors in a randomized clinical trial of methadone maintenance treatment. American Journal on Addictions. 21, 476-487. PMCID: PMC3422766. doi: 10.1111/j.1521-0391.2012.00250.x. PMID: 22882399. PMCID: PMC3422766.
Gryczynski J, Mitchell SG, Peterson TR, Gonzales A, Moseley A, Schwartz RP (2011). The relationship between services delivered and substance use outcomes in New Mexico's Screening, Brief Intervention, Referral and Treatment (SBIRT) Initiative. Drug and Alcohol Dependence. 118 (2-3), 152-157. [PMCID: PMC21482039].
Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH (2011). Patterns in admission delays to outpatient methadone treatment in the United States. Journal of Substance Abuse Treatment. 41 (4), 431-439. [PMCID: PMC3205308].
Katz EC, Brown BS, Schwartz RP, O’Grady KE, King SD, Gandhi D (2011). Transitioning opioid-dependent patients from detoxification to long-term treatment: Efficacy of intensive role induction. Drug and Alcohol Dependence. 117 (1), 24-30. [PMCID: PMC3090541].
Kelly SM, O’Grady KE, Mitchell SG, Brown BS, Schwartz RP (2011). Predictors of methadone treatment retention from a multi-site study: A survival analysis. Drug and Alcohol Dependence. 117. (2-3), 170-175. [PMCID: PMC3148301].
Kinlock TW, Gordon MS, Schwartz RP (2011). Incarcerated populations. In P. Ruiz & E. Strain (Eds.). Lowinson & Ruiz’s Substance Abuse: A Comprehensive Textbook. (Fifth ed., pp. 881-891). Philadelphia, PA: Lippincott Williams & Wilkins.
Mitchell SG, Morioka R, Reisinger HS, Peterson JA, Kelly SM, Agar MH, Schwartz RP, et al (2011). Redefining retention: recovery from the patient's perspective. Journal of Psychoactive Drugs. 43 (2), 99-107. [PMCID: PMC3160714].
Rich JD, McKenzie M, Dickman S, Bratberg J, Lee JD, Schwartz RP (2011). An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report. Addictive Disorders and their Treatment. 10 (4), 199-200. PMCID: PMC3222590.
Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH (2011). Interim methadone treatment compared to standard methadone treatment: 4-Month findings. Journal of Substance Abuse Treatment. 41 (1), 21-29. [PMCID: PMC3110526].
Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Brown BS (2011). Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts. Drug and Alcohol Dependence. 115 (1-2), 23-29. [PMCID: PMC3059350].
Schwartz RP, Mitchell SG, Gordon MS, and Kinlock TW (2011). Pharmocotherapy. In C. Leukefeld, J. Gregrich & T. P. Gullotta (Eds.), . Handbook on Evidence-Based Substance Abuse Treatment Practice in Criminal Justice Settings, Issues in Childrens’ and Families’ Lives 11.  (pp. 259-277). New York: Springer Publishing.
Kelly SM, O’Grady KE, Brown BS, Mitchell SG, Schwartz RP (2010). The role of patient satisfaction in methadone treatment. American Journal of Drug and Alcohol Abuse, 36. (3), 150-154. [PMCID: PMC2938880].
Kelly SM, O’Grady KE, Schwartz RP, Peterson JA, Wilson ME, Brown BS (2010). The relationship of social support to treatment entry and engagement: The community assessment inventory. Substance Abuse. 31 (1), 43-52. [PMCID: PMC2856126].
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT (2010). Developing and implementing a new prison-based buprenorphine treatment program. Journal of Offender Rehabilitation. 49 (2), 91-109. [PMCID: PMC2868193].
Peterson JA, Schwartz RP, Mitchell SG, Reisinger HS, Kelly SM, O’Grady KE, Brown BS, Agar MH (2010). Why don’t out-of-treatment individuals enter methadone treatment programs? International Journal of Drug Policy. 21 36-42. [PMCID: PMC2790538].
Wilson ME, Schwartz RP, O’Grady KE, Jaffe JH (2010). Impact of interim methadone maintenance on HIV risk behaviors. Journal of Urban Health. 87 (4), 586-591. [PMCID: PMC2900571].
Chandler RK, Dennis ML, El-Bassel N, Schwartz RP, Field G (2009). Ensuring safety, implementation and scientific integrity of clinical trials: less from the Criminal Justice-Drug Abuse Treatment Studies Data and Safety Monitoring Board. Journal of Experimental Criminology. 5(3), 324-244.
Gryczynski J, Schwartz RP, O’Grady K, Jaffe JH (2009). Dropout from interim methadone and subsequent comprehensive methadone maintenance. American Journal of Drug and Alcohol Abuse. 35, 394-398.
Gryczynski J, Schwartz RP, O’Grady K, Jaffe JH (2009). Treatment entry among individuals on a waiting list for methadone maintenance.  American Journal of Drug and Alcohol Abuse. 35(5), 290-294. Abstract.
Katz EC, Schwartz RP, King SD, Highfield DA, O’Grady KE, Billings T, Gandhi D, Weintraub E, Glovinsky D, Barksdale W, Brown BS (2009). Brief v. extended buprenorphine detoxification in a community treatment program: Engagement and short-term outcomes.  American Journal of Drug and Alcohol Dependence.
Kelly SM, Schwartz RP, O’Grady KE, Mitchell SG, Reisinger HS, Peterson JA, Agar MH, Brown BS (2009). Gender differences among in- and out-of-treatment opioid-addicted individuals. American Journal of Drug and Alcohol Abuse. 35, 38-42.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE (2009). Methadone maintenance for prisoners: Results at twelve-months post-release. Journal of Substance Abuse Treatment. 37, 277-285.
Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Ruhf A, Agar MH, O’Grady KE Schwartz RP (2009). Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. The American Journal on Addictions.
Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Ruhf A, Agar MH, Schwartz RP (2009). Incarceration and opioid withdrawal: The experiences of methadone patients and out-of-treatment heroin users.  Journal of Psychoactive Drugs.
Schwartz RP, Jaffe JH, O’Grady K, Das B, Highfield DA, Wilson ME (2009). Scaling-up interim methadone maintenance: Treatment for 1,000 heroin addicts. Journal of Substance Abuse Treatment. 37(4), 362-367. PMCID: PMC2796977.
Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A (2009). Interim Methadone Treatment: Impact on Arrests.  Drug and Alcohol Dependence. 103, 148-154. doi: 10.1016/j.drugalcdep.2009.03.007. Epub 2009 May 14. PMID: 19443133.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE (2008). A randomized clinical trial of methadone maintenance for prisoners: Findings at 6-months post-release. Addiction. 103 (8), 1333-1342.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2008). A study of methadone maintenance for male prisoners: Three-month post-release outcomes. Criminal Justice and Behavior. 35 (1), 34-47.
Peterson JP, Schacht-Reisinger H, Schwartz RP, Mitchell SG, Kelly SM, Brown BS, Agar MH (2008). Targeted sampling in drug abuse research: A review and case study.  Field Methods. 20(2), 155-170.
Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O’Grady KE, Marrari EA, Brown BS, Agar MH (2008). Premature discharge from methadone treatment: Patient perspectives. Journal of Psychoactive Drugs.
Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Peterson JA, Reisinger HS, Agar MH, Brown BS (2008). Attitudes toward buprenorphine and methadone among opioid-dependent individuals. American Journal on Addictions. 17(5), 396-401.
Schwartz RP, Kelly SM, O’Grady KE, Peterson JA, Reisinger HS, Mitchell SG, Wilson ME, Agar MH, Brown BS (2008). In-treatment v. out-of-treatment opioid dependent adults: Drug use and criminal history. American Journal of Drug and Alcohol Abuse. 34(1), 17-28.
Garcia CA, Caraballo Correa G, Hernandez Viver AD, Kinlock TW, Gordon MS, Antron Avila C, Colón Reyes I, Schwartz RP (2007). Buprenorphine-Naloxone Treatment for Pre-release Opioid Dependent Inmates in Puerto Rico. Journal of Addiction Medicine. 1(6), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947.
Garcia CA, Correa GC, Hernandez Viver AD, Kinlock TW, Gordon MS, Avila CA, Reyes CI, Schwartz RP (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal on Addiction Medicine. 1(3), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947.
Highfield DA, Schwartz RP, Jaffe JH, Callaman J, O’Grady KE (2007). Intravenous and intranasal heroin dependent treatment seekers: Similarities and differences. Addiction. 102(11), 1816-23. Epub 2007 Sep 3. PMID: 17784892.
Katz EC, Brown BS, Schwartz RP, King SD, Weintraub E, Barksdale W (2007). Impact of role induction on long-term drug treatment outcomes. Journal of Addictive Diseases. 26, 81-90. PMID: 17595001.
Katz ES, Brown BS, Schwartz RP, King SD, Weintraub E, and Barksdale W (2007). Impact of role induction on long-term treatment outcome. Journal of Addictive Diseases. 26(2):81-90.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug and Alcohol Dependence. 91(2-3), 220-227. Epub 2007 Jul 12. PMID: 17628351PMCID: PMC2423344.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). Examining the Effectiveness of Opioid Agonist Programs for Prisoners at One Month Following Release from Incarceration. Drug and Alcohol Dependence. 91 (2-3), 220-227.
Schwartz RP, Highfield DA, Jaffe JH, Callaman JM, O’Grady KE (2007). A randomized controlled trial of interim methadone maintenance: 10 month-follow-up. Drug and Alcohol Dependence. 86, 30-36. Epub 2006 Jun 21. PMID: 16793221.
Schwartz RP, McKenzie M, Rich JD, (2007). Opioid addiction and incarceration: an overview. Medicine and Health/Rhode Island. 90, 157-158. PMID: 17557660.
King VL, Stoller KB, Kidorf MS, Kolodner K, Schwartz RP, Brooner RK (2006). A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. Journal of Substance Abuse Treatment. 31, 385-93.
Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O’Grady KE, and Battjes RJ (2006). A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry. 63(1), 102-109. PMID: 16389204.
Katz EC, Brown B, Schwartz RP, and Weintraub E (2005). Cognitive ability as a factor in engagement in drug abuse treatment. American Journal of Drug and Alcohol Abuse. 31(3), 359-69. PMID: 16161723.
Kinlock TW, Battjes RJ, Schwartz RP (2005). A novel opioid maintenance treatment program for prisoners: Report of post-release outcomes. American Journal of Drug and Alcohol Abuse. 31, 433-454. PMID: 16161728.
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoner. Corrections Compendium. 30(3), 6-30.
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoners. Corrections Compendium. 30(3), 28-30.
Katz EC, Brown BS, Schwartz RP, Weintraub E, Barksdale W, and Robinson R (2004). Role induction: A method for enhancing early retention in outpatient drug-free treatment. Journal of Consulting and Clinical Psychology. 72, 227-234.
Loughlin A, Schwartz RP, and Strathdee SA (2004). Prevalence and correlates of HCV infection among methadone maintenance attendees: Implications for HCV treatment. International Journal of Drug and Policy. 15, 93-101.
Johnson JL, Wiechelt SA, Schwartz R, Ahmed A (2003). Outcomes for substance abuse treatment in women: Results from the Baltimore City Treatment Evaluation study. Journal of Substance Use and Misuse. 38, 1807-29. PMID: 14582579.
Kuo I, Brady J, Butler C, Schwartz RP, Brooner R, Vlahov D, and Strathdee S (2003). Feasibility of a drug treatment program using LAAM for drug users referred from a needle exchange program. Journal of Substance Abuse Treatment. 24, 67-74.
DiPaula B, Schwartz RP, Montoya ID (2002). Heroin detoxification with buprenorphine on an inpatient psychiatric hospital unit. Journal of Substance Abuse Treatment. 23, 163-169.
King VL, Stoller KB, Hayes M, Umbricht A, Curran M, Kidorf MS, Carter JA, Schwartz RP, and Brooner RK (2002). A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence. 65,137-148.
Kinlock TW, Battjes RJ, Schwartz RP (2002). A novel opioid maintenance program for prisoners: Preliminary findings. Journal of Substance Abuse Treatment. 22, 141-147. PMID: 12039617. PMID: 12039617.
Weintraub E, Dixon L, Delahanty J, Schwartz R, Johnson J, Cohen A, Klecz M (2001). Reason for medical hospitalization among adult alcohol and drug abusers. American Journal on Addictions. 10, 167-77.
Eldefrawi ME, Azer NL, Nath N, Anis NA, Bangalore MS, O’Connell KP, Schwartz RP, and Wright J (2000). An automated solid phase fluoroimmunoassay for detection of heroin and cocaine metabolites in urine. Applied Biochemistry and Biotechnology. 87, 25-35.
Aszalos RA, McDuff DR, Weintraub E, Montoya IM, Schwartz RP (1999). Engaging hospitalized heroin-dependent patients into substance abuse treatment. Journal of Substance Abuse Treatment. 17, 149-158.
O’Connell KP, Valdes JJ, Azer NL, Schwartz RP, Wright J, and Eldefrawi ME (1999). Assessment of a multichannel automated solid phase competitive fluoroimmunoassay for benzoylecognine in untreated urine. Journal of Immunological Methods. 251, 157-169.
Schwartz RP, Brooner RK, Montoya I D, Currens M, and Hayes M (1999). A 12-year follow-up of a methadone medical maintenance program. American Journal on Addictions. 8(4), 293-299.
Boyd SJ, Plemons BW, Schwartz RP, Johnson JL, and Pickens RW (1998). The relationship between parental history and substance use severity in drug treatment patients. American Journal on Addictions. 8, 15-23.
Bueger M, Tommasello AT, Schwartz RP, and Clinton M (1998). Clonidine use and abuse among methadone program applicants and patients. Journal of Substance Abuse Treatment. 15, 589-593.
Schwartz RP, and Tommasello AT (1997). The Medical Maintenance Model and the Pharmacist. Journal of Pharmacy Practice and Research. 10, 346-351.
White RK, McDuff DR, Schwartz RP, Tiegel S and Judge C (1996). New developments in employee assistance programs. Psychiatric Services. 47,387-392.
Schwartz R, Johnson JL, McDuff DR, Tiegel S, and Bell L (1995). Evaluation of addictions training for psychiatric residents. Substance Abuse. 16, 1-8.
Schwartz R, White RK, McDuff DR, Johnson JL (1995). Four year’s experience of a hospital's impaired physician committee. Journal of Addictive Diseases. 14, 13-21.
Lehman A, Herron J, Schwartz R, and Myers CP (1993). Rehabilitation for young adults with severe Mental illness and substance use disorders: A clinical trial. Journal of Nervous and Mental Disease. 181, 86-90.
McDuff D, Schwartz R, Tommasello A, Tiegel S, Donovan T, Johnson J (1993). Preliminary report outpatient benzodiazepine detoxification procedure for methadone patients. Journal of Substance Abuse Treatment. I, 97-302.
White R, Schwartz R, McDuff DR, and Hartmann P (1992). Hospital-based professional assistance committees: Literature review and guidelines. Maryland Medical Journal. 41(4), 305-9.